Back to Authors

Bennett, Jeffrey L

0000-0002-3346-1394

Mayo Clinic

Departments of Neurology and Ophthalmology, Program in Neuroscience, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA. richard.ransohoff@biogen.com jeffrey.bennett@ucdenver.edu.

Citations 19

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

Annals of Neurology | March 3, 2023 | Volume: 93 | Issue: 6 | Pages: 1053-1068

10.1002/ana.26626 | PMID 36866852

Objective CHAMPION‐NMOSD (NCT04201262) is a phase 3, open‐label, externally controlled interventional study evaluating the efficacy and safety of the terminal complement inhibitor ravulizumab in adult patients with anti–aquaporin‐4 antibody–positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab binds the same complement component 5 epitope as the approved therapeutic eculizumab but has a longer half‐life, enabling an extended dosing interval (8 vs 2 weeks). Methods The availability of eculizumab precluded the use of a concurrent placebo control in CHAMPION‐NMOSD; consequently, the placebo group of the eculizumab phase 3 trial PREVENT (n = 47) was used as an external comparator. Patients received weight‐based intravenous ravulizumab on day 1 and maintenance doses on day 15, then once every 8 weeks. The primary endpoint was time to first adjudicated on‐trial relapse. Results The primary endpoint was met; no patients taking ravulizumab (n = 58) had an adjudicated relapse (during 84.0 patient‐years of treatment) versus 20 patients with adjudicated relapses in the placebo group of PREVENT (during 46.9 patient‐years; relapse risk reduction = 98.6%, 95% confidence interval = 89.7%–100.0%, p < 0.0001). Median (range) study period follow‐up time was 73.5 (11.0–117.7) weeks for ravulizumab. Most treatment‐emergent adverse events were mild/moderate; no deaths were reported. Two patients taking ravulizumab experienced meningococcal infections. Both recovered with no sequelae; one continued ravulizumab treatment. Interpretation Ravulizumab significantly reduced relapse risk in patients with AQP4+ NMOSD, with a safety profile consistent with those of eculizumab and ravulizumab across all approved indications. ANN NEUROL 2023;93:1053–1068
Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

JAMA Neurology | April 4, 2022 | Volume: 79 | Issue: 5 | Pages: 518

10.1001/jamaneurol.2022.0489 | PMID 35377395

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

Neurology Neuroimmunology & Neuroinflammation | March 26, 2021 | Volume: 8 | Issue: 3 | Pages: No page available

10.1212/nxi.0000000000000978 | PMID 33771837

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD

Multiple Sclerosis Journal | February 9, 2021 | Volume: 27 | Issue: 13 | Pages: 2052-2061

10.1177/1352458521988926 | PMID 33538237

Background: In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo. Objective: To demonstrate the robustness of this finding, using pre-specified sensitivity and subgroup analyses. Methods: N-MOmentum is a prospective, randomized, placebo-controlled, double-masked trial of inebilizumab, an anti-CD19 monoclonal B-cell-depleting antibody, in patients with NMOSD. Pre-planned and post hoc analyses were performed to evaluate the primary endpoint across a range of attack definitions and demographic groups, as well as key secondary endpoints. Results: In the N-MOmentum trial (ClinicalTrials.gov: NCT02200770), 174 participants received inebilizumab and 56 received placebo. Attack risk for inebilizumab versus placebo was consistently and significantly reduced, regardless of attack definition, type of attack, baseline disability, ethnicity, treatment history, or disease course (all with hazard ratios < 0.4 favoring inebilizumab, p < 0.05). Analyses of secondary endpoints showed similar trends. Conclusion: N-MOmentum demonstrated that inebilizumab provides a robust reduction in the risk of NMOSD attacks regardless of attack evaluation method, attack type, patient demographics, or previous therapy. The N-MOmentum study is registered at ClinicalTrials.gov: NCT2200770.
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

Neurology | June 18, 2020 | Volume: 95 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000009758 | PMID 32554760

Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica

Science Translational Medicine | October 12, 2017 | Volume: 9 | Issue: 397 | Pages: No page available

10.1126/scitranslmed.aai9111 | PMID 28679661

An autoantibody target on brain microvascular endothelial cells in patients with neuromyelitis optica may be exploited to manipulate blood-brain barrier permeability.
Placebo-controlled study in neuromyelitis optica—Ethical and design considerations

Multiple Sclerosis Journal | December 14, 2015 | Volume: 22 | Issue: 7 | Pages: 862-872

10.1177/1352458515620934 | PMID 26666258

Background: To date, no treatment for neuromyelitis optica (NMO) has been granted regulatory approval, and no controlled clinical studies have been reported. Objective: To design a placebo-controlled study in NMO that appropriately balances patient safety and clinical–scientific integrity. Methods: We assessed the “standard of care” for NMO to establish the ethical framework for a placebo-controlled trial. We implemented measures that balance the need for scientific robustness while mitigating the risks associated with a placebo-controlled study. The medical or scientific community, patient organizations, and regulatory authorities were engaged early in discussions on this placebo-controlled study, and their input contributed to the final study design. Results: The N-MOmentum study (NCT02200770) is a clinical trial that randomizes NMO patients to receive MEDI-551, a monoclonal antibody that depletes CD19+ B-cells, or placebo. The study design has received regulatory, ethical, clinical, and patient approval in over 100 clinical sites in more than 20 countries worldwide. Conclusion: The approach we took in the design of the N-MOmentum trial might serve as a roadmap for other rare severe diseases when there is no proven therapy and no established clinical development path.
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Neurology | June 19, 2015 | Volume: 85 | Issue: 2 | Pages: 177-189

10.1212/wnl.0000000000001729 | PMID 26092914

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder

JAMA Neurology | May 26, 2015 | Volume: 72 | Issue: 7 | Pages: 815

10.1001/jamaneurol.2015.0248 | PMID 26010909